PTN - Palatin Technologies, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

PTN

PALATIN TECHNOLOGIES, INC.

NASDAQ

$10.86

▲ UP 4.12% (0.43)

KEY STATISTICS

Market Cap$19.32 M

52w High$31.00

52w Low$5.61

Dividend Yield—

Frequency—

P/E98.73

Volume51.56K

Shares Out.1.78M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Carl Spana

COMPENSATION 2026

Salary$721,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$17,500

Total$738,500

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 15, 1997

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$47.50

Target Low$47.50

Target Median$47.50

Target Consensus$47.50

UPCOMING EARNINGS

DateNov 16, 2026

DayMonday

Rev. Est.—

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-08-12	Reverse	1:50
2022-08-31	Reverse	1:25
2010-09-27	Reverse	1:10
1997-09-08	Reverse	1:4
1996-07-22	Reverse	1:10

PRICE

$10.86 ▲ UP 4.12% (+$0.43)

OVERLAYS

About Palatin Technologies, Inc.

https://palatin.com ↗

Palatin Technologies, Inc. is a biopharmaceutical company developing first-in-class melanocortin receptor modulators for obesity, dry eye, inflammatory diseases, and ED, with several products in preclinical and clinical stages.

INDUSTRY

Biotechnology

A PRODUCT PALATIN TECHNOLOGIES, INC. IS KNOWN FOR

PL9643

PL9643 is an investigational melanocortin agonist for dry eye disease, having completed Phase 3 trials and received FDA protocol approval for two more studies.